Finance

Lists
603520:SHA
Zhejiang Starry Pharmaceutical Co Ltd
CNÂ¥8.64
-0.23%
(-0.020) 1D
Sep 23, 3:00:01 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603520...
Open
CNÂ¥8.64
High
CNÂ¥8.74
Low
CNÂ¥8.57
Mkt. cap
3.77B
Avg. vol.
6.90M
Volume
5.26M
Dividend
3.47%
Quarterly dividend
CNÂ¥0.08
Ex-dividend date
Sep 11, 2026
P/E ratio
187.62
52-wk high
CNÂ¥14.37
52-wk low
CNÂ¥7.89
EPS
CNÂ¥0.05
Shares outstanding
120.00M
No. of employees
2K
Open
CNÂ¥8.64
High
CNÂ¥8.74
Low
CNÂ¥8.57
Mkt. cap
3.77B
Avg. vol.
6.90M
Volume
5.26M
Dividend
3.47%
Quarterly dividend
CNÂ¥0.08
Ex-dividend date
Sep 11, 2026
P/E ratio
187.62
52-wk high
CNÂ¥14.37
52-wk low
CNÂ¥7.89
EPS
CNÂ¥0.05
Shares outstanding
120.00M
No. of employees
2K
About Zhejiang Starry Pharmaceutical Co Ltd
CEO-
Employees1.9K
FoundedSep 15, 1997
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
447.26M
600.76M
711.27M
703.00M
Cost of goods sold
315.76M
530.64M
552.98M
576.59M
Cost of revenue
315.76M
530.64M
552.98M
576.59M
Research and development expenses
28.97M
37.20M
28.28M
30.92M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
68.25M
55.26M
65.75M
65.82M
Operating expense
85.31M
100.75M
96.26M
88.22M
Total operating expenses
401.07M
631.39M
649.25M
664.81M
Operating income
46.19M
-30.63M
62.02M
38.19M
Other non operating income
9.79M
-17.11M
-10.36M
-41.58M
EBT including unusual items
-1.25M
-30.84M
27.63M
26.02M
EBT excluding unusual items
22.63M
-46.43M
33.32M
37.88M
Income tax expense
-944.92K
-11.95M
6.82M
6.91M
Effective tax rate
75.71%
38.76%
24.67%
26.56%
Other operating expenses
-8.07M
8.64M
-3.30M
-2.98M
Net income
-310.63K
-18.60M
20.95M
18.98M
Net profit margin
-0.07%
-3.10%
2.95%
2.70%
Earnings per share
-
-
-
-
Interest and investment income
374.11K
360.05K
373.10K
41.28M
Interest expense
-17.36M
-19.19M
-18.71M
-
Net interest expenses
-16.99M
-18.83M
-18.34M
41.28M
Depreciation and amortization charges
-
-
-
-
EBITDA
100.91M
28.95M
121.60M
98.54M
Gain or loss from assets sale
262.77K
-447.30K
-
29.94K
AI content may include mistakes. Learn more
Google apps